Novartis, Merck KGaA and Biogen: Which new MS drug do doctors like best? You might be surprised

19th November 2019 Uncategorised 0

While new multiple sclerosis drugs from Novartis, Merck KGaA and Biogen have hit the market this year, all bearing blockbuster hopes, one group of doctors wasn’t all that interested in them. Instead, a repurposed therapy not yet approved for MS attracted “unanimous excitement,” an analyst said.

More: Novartis, Merck KGaA and Biogen: Which new MS drug do doctors like best? You might be surprised
Source: fierce